ArticleInternational journal of women's health2026
Metabolic Syndrome Predicts Chemotherapy Resistance and Poor Prognosis in Epithelial Ovarian Cancer: A Retrospective Observational Cohort Study.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the association between metabolic syndrome and chemotherapy resistance, as well as its prognostic significance in patients with epithelial ovarian cancer. Materials and Methods: This single-center retrospective observational cohort study analyzed clinical data from 513 patients with histologically confirmed epithelial ovarian cancer who underwent cytoreductive surgery followed by standard platinum-based chemotherapy at The First Affiliated Hospital of Chengdu Medical College between January 2019 and December 2021. Metabolic syndrome was diagnosed according to the International Diabetes Federation criteria. Follow-up data were collected through outpatient visits and telephone interviews, and overall survival and progression-free survival were recorded. Survival outcomes were evaluated using Kaplan-Meier analysis. Multivariable Cox proportional hazards regression models were employed to identify independent prognostic factors after adjustment for clinically relevant confounders, including age, histological subtype, FIGO stage, surgical completeness, chemotherapy response, and maintenance therapy. Results: Among the 513 included patients, 180 (35.09%) were diagnosed with metabolic syndrome. Patients with metabolic syndrome had significantly higher body mass index, advanced FIGO stages, higher prevalence of diabetes, hypertension, dyslipidemia, and higher rates of chemotherapy resistance compared to those without metabolic syndrome. Kaplan-Meier analysis showed that patients with metabolic syndrome had significantly shorter overall survival and progression-free survival compared with patients without metabolic syndrome. In multivariable Cox regression analysis, metabolic syndrome remained independently associated with poorer overall survival and progression-free survival after adjustment for potential confounding factors. Conclusion: Metabolic syndrome is significantly associated with chemotherapy resistance and poor prognosis in patients with epithelial ovarian cancer. These findings suggest that metabolic syndrome may serve as a useful clinical indicator for risk stratification. However, because this was a single-center retrospective observational study, causal relationships cannot be established. Further prospective multicenter studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.